Highly-Targeted Epigenomic Treatments May Change Cancer Therapy
(firmenpresse) - NEW YORK, NY -- (Marketwire) -- 08/24/12 -- A new shift in thinking about could transform cancer treatment over the next five years, according to Kalorama Information. The says therapies such as monoclonal antibodies may have competition from an unexpected source: changes in the genetic material that occur for reasons other than base pair alteration. The finding was made in its recent report, "."
constitutes a challenge to the long-held paradigm of DNA base pair sequences as the prime determinant of the phenotype. Examples of such changes include DNA methylation and histone acetylation, both of which have been known for many years to cause changes in . The report says that drugs that target the offer a number of important advantages over other forms of ; most notably they can be taken orally, saving the patient discomfort, cost and inconvenience. They are also more focused specifically against their target.
"Rather than blasting away machine gun style at the malignancy, they aim at a very specific reaction site within the cell," said K. John Morrow, Jr., PhD, Kalorama analyst and author of the report. "So far their side effects have proven to be relatively minor."
The report says that while epigenomic therapeutics have been around for a while, a raft of new clinical trials are in progress, and with any luck the next few years will see a number of FDA approvals for these agents. There are already FDA-approved anti-cancer drugs available, such as azacytidine, and trials are underway that combine a non-epigenetically-based drug with one of the compounds under evaluation.
Perhaps the only concern to companies wishing to pursue the Kalorama recommendation is the competition, the fact that so many of the major pharmaceutical and biotech players are already building vigorous epigenomics programs. These programs include investigations into epigenomic mechanisms that engage cardiovascular disease and neurological dysfunction. Some may see these as non-cancer-related but they are. It is known that flexible epigenomic parameters exist that can change gene expression under external influences, while endowed with the ability to stably propagate these modifications from one generation to the next.
"At present the major pharmaceutical companies are faced with a downward spiral of profitability," Morrow said. "Epigenomic technologies represent an escape from this corrosive cycle of greater and greater R&D expenditures and poorer and poorer yields of FDA-approved pharmaceuticals."
Kalorama Information's report, "," has an extensive survey of information on market forecasts and company activities in the marketplace.
Kalorama Information, a division of MarketResearch.com, supplies the latest in independent in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on , and our .
Please direct all media inquiries to:
Bruce Carlson
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 24.08.2012 - 15:35 Uhr
Sprache: Deutsch
News-ID 177470
Anzahl Zeichen: 0
contact information:
Town:
NEW YORK, NY
Kategorie:
Hospitals, Facilities and Providers
Diese Pressemitteilung wurde bisher 231 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Highly-Targeted Epigenomic Treatments May Change Cancer Therapy"
steht unter der journalistisch-redaktionellen Verantwortung von
Kalorama Information (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
